9 results about "Complement Factor D" patented technology

Disclosed in the present invention are a preparation method for a complement factor D inhibitor, an intermediate thereof, and a preparation method for an intermediate. The present invention provides a preparation method for a new complement factor D inhibitor, a new intermediate, and a preparation method for an intermediate. The selectivity of a reaction is improved by means of the new intermediate, the material conversion rate of each step of a route is high, a reaction type is common, the length of the route is moderate, and the obtained products can all be purified by means of a conventional method to obtain a target product, thereby reducing the production costs, and facilitating industrial production.

The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

Provided herein are dual-antigen binding molecules, and nucleic acid sequences encoding such molecules, that bind human complement factor D (FD) and human complement component 2 (C2). In particular embodiments, the FD binding region of the dual-antigen binding molecules comprises light and heavy chain variable regions, and the C2 binding region comprises a first single monomeric variable antibody domain (aka VHH), and optionally second single monomeric variable antibody domain. In certain embodiments, the dual-antigen binding molecules are used to treat complement-related diseases (e.g., dysregulated complement activation diseases).

The present invention provides multispecific (e.g., bispecific) constructs that target complement factor D and another complement protein (e.g., C2, C5), nucleic acids encoding such multispecific constructs, and their use for the treatment of complement mediated diseases. Also provided are novel antibody constructs that specifically recognize C5, nucleic acids encoding the antibody constructs, and uses thereof.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

The present disclosure relates generally to methods of treating a subject having or at risk of developing macular degeneration by administering a complement factor D (CFD) inhibitor to the subject and to identifying subjects at increased risk of developing macular degeneration.

The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof. The methods involve subjecting an intermediate in the synthesis of a complement factor D inhibitor to a t-butyl ester deprotection reaction using a weak base.

Disclosed in the present invention are a compound as a complement factor D inhibitor, a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a compound as represented by formula (I), a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a solvate of any of the foregoing. The compound has a good inhibitory activity on complement factor D, and exhibits good pharmacokinetic and pharmacodynamic activities.

Disclosed are compounds of formula (I), and pharmaceutically acceptable salts thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.